|Articles|June 9, 2022

Owkin Announces Collaboration with Bristol Myers Squibb

Collaboration model will apply AI to optimize design and reduce the cost of clinical trials, initially in cardiovascular disease.

Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence (AI) capabilities to design clinical trials for Bristol Myers Squibb. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas.